INTRODUCTION
Glioblastoma (GBM), a grade IV glioma classified by World Health Organization (WHO), is considered highly malignant, vascular and invasive subtype. 1 GBM is most lethal during first year after initial diagnosis despite surgical resection, radiotherapy and/or chemotherapy 1, 2 .
Hypoxia and neovascularization are histopathologic features of GBM 3 . Because of hypervascular nature of GBM, anti-angiogenic therapies (AAT) were used as an adjuvant mainly against VEGF-VEGFR pathway to normalize tumor vasculatures. Regrettably, benefits of antiangiogenic therapy are at best transitory, and this period of clinical benefit (measured in weeks or months) is followed by restoration of tumor growth and progression [4] [5] [6] [7] . Agents that interfere with VEGF-VEGFR signal transduction pathway, such as vetanalib (PTK787), cediranib, sunitinib, etc have been used in clinical trials with varying degree of success 8, 9 .
Evidence of relapse to progressive tumor growth following treatment reflects development of resistance to antiangiogenic therapies 10 . One possible mechanism for resistance to antiangiogenic therapy might be the activation of alternative angiogenesis signaling pathways, such as basic fibroblast growth factor (bFGF), Tie-2, stromal-cell derived factor-1α (SDF-1α), and increased VEGF production leading to increased invasiveness of the tumor cells 9, 11, 12 . A second additional and distinct potential mechanism of resistance might be recruitment of endothelial progenitor cells (EPCs) and pro-angiogenic monocytes from the bone marrow. Hypoxia creates conditions permissive for the recruitment of a heterogeneous population of bone marrow-derived monocytic cells that promotes angiogenesis and growth. However, animal models to in vivo track the migration and accumulation of BMDCs to the tumors are rare.
Current evidences from recent publications indicate the involvement of both angiogenesis and vasculogenesis processes for glioma growth (tumor growth) [13] [14] [15] . With an emerging new 4 insights into vasculogenesis, investigators are looking into possible mechanisms how bone marrow derived progenitor cells (BMPCs) or EPCs migrate and incorporate into tumor neovascularization 16 . One of the mechanisms, which has been pointed out is the involvement of SDF-1-CXCR4 axis [17] [18] [19] . SDF-1α is a chemokine that is expressed in tumor cells and released in the circulation following hypoxia in the tumor (with the up-regulation of HIF-1α) [20] [21] [22] . In an experiment, Heissig et al 23 determined the mechanisms of releasing hematopoietic stem cells (HSC) and EPCs from bone marrow. SDF-1α is a strong chemo-attractant for CXCR4 positive cells. Preventing interaction of SDF-1-CXCR4 is thought to be a mechanism to block vasculogenesis. AMD3100, a receptor (CXCR4) antagonist was initially developed as anti HIV drug and later used to mobilize CD34+ HSCs cells to the peripheral circulation 19 . Although AMD3100 increased the number of peripheral CD34+ or progenitor cells, the recent investigations pointed out that continuous treatment with AMD3100 or similar CXCR4 receptor antagonists inhibit vasculogenesis in tumors causing inhibition of tumor growth 19, 24 . In vivo determination of bone marrow cell mobilization and accumulation to tumor periphery and its effect in developing tumor resistance to antiangiogenic therapy would be invaluable 25 . 
RESULTS

Establishing chimeric mouse model
Athymic nude mice (n=3, each group) were transplanted with 5x10 6 BM cells from GFP+ mouse after whole body irradiation of sub-lethal dose (6Gy). Engraftment efficiency (GFP+) was determined at each week (Days 7 to 56) (Fig 1A) . Engraftment efficiency for NOD-SCID chimera was determined at different time points (Days 14 and 28) (Supplementary Fig 1A) .
Non-injected group (non-irradiated) were used as control for flow cytometry gating. Highest engraftment efficiency of 22.3 % was achieved using i.p. injection (n=3) on day 56 (middle panel)
. Surprisingly, i.v. injection (n=3) of 5x10 6 mononuclear cells achieved >70% engraftment by day 14 and >80 % engraftment by day 56 (lower panel) (Fig 1B) . We decided to use i.v.
injection of 5x10 6 BM cells and 14 days waiting to establish chimera for tumor studies.
However, in NOD-SCID chimera, 50% of mice showed more than 70% engraftment achieved by day 14 and 76% of mice displayed 83-87 % engraftment by day 28 (Supplementary Fig 1B) .
Effect of treatments on tumor growth
Chimeric athymic nude mice were implanted orthotopically with U251 cells and treated with vehicle (n=17), vatalanib (n=10), AMD3100 (n=9), and nintedanib (n=3) from day 8-21. All animals underwent MRI on day 22 (Fig 2A and 2B) . We selected vatalanib as AAT agent because these drugs enhanced tumor growth and activated alternate pathways of neovascularization in GBM 30, 31 . Nintedanib was used to investigate the effect of multi-tyrosine kinase inhibition in GBM. In addition, AMD3100 is an immunostimulant used to mobilize bonemarrow derived hematopoietic stem cells in tumor. We observed no significant decrease in tumor growth after vatalanib and AMD3100 treatment. Nintedanib treatment resulted 7 in increased tumor growth as observed by MRI and tumor volume data (Fig 2A and 2B) . NOD-SCID chimera (n=6) were orthotopically implanted with GBM PDX cells for tumor studies.
However, we could not perform MRI with NOD-SCID chimera due to unexpected sickness.
NOD-SCID mice were euthanized, whenever sign of sickness were seen.
Effect of treatments on infiltration of GFP+ cells in the tumor
In vivo optical images obtained on days 7, 14 and 21 showed more accumulation of GFP+ in tumor following treatments (yellow arrows) compared to vehicle (Fig 3A and 3B ). Nintedanib and AMD3100 treatments showed increased accumulation of GFP+ cells in tumor at day 14 compared to vehicle group (yellow arrows). At day 21, optical images showed increased infiltration of GFP+ cells in vatalanib, nintedanib and AMD3100 treated groups compared to vehicle (yellow arrows). Similarly, flow cytometry data at the end of the study (day 22) proved higher number of GFP+ cells in drug treated tumors compared to vehicle, especially with nintedanib treatment (Fig 3C,) . GBM PDX bearing NOD-SCID chimera were scanned on days 14 and 18, which showed accumulation of GFP+ in the tumor regions of the brain ( Supplementary Fig 2A and B) . In addition, ex-vivo imaging following mice euthanasia showed accumulation of GFP+ in the tumor regions of the brain (Supplementary Fig 2C) .
Effect of vatalanib, nintedanib and AMD3100 on myeloid and endothelial cell signatures
Post-MRI, brain, spleen and BM were collected and processed for flowcytometry to analyze immune cell signatures (spleen and BM data not shown). Vatalanib treatment significantly increased both myeloid signature (CD68) and endothelial signatures (CD133, CD31, CD202b, CD34) compared to vehicle (Fig 4A and 4B ). In addition, significant increase in endothelial cell 8 signatures (CD133 and CD31) was seen in nintedanib group compared to vehicle (Fig 4A and   4B ). Please note we did not performt CD68, CD202b and CD34 stainings in nintedanib group (Fig 4A and 4B) . No significant changes in myeloid and endothelial cell signatures were seen in AMD3100 group (Fig 4A and 4B) . In addition, rumor brains from NOD-SCID chimera bearing GBM PDX were collected on day 18 and processed for flow cytometry analysis. Tumor Fig 3A) . High GFP Fig 3B) .
Homing sites and phenotypes of infiltrated GFP+ cells
Immunofluorescence study showed accumulation of GFP+ cells at the tumor periphery or invasive front in vatalanib treated group (yellow arrow). Vehicle and other treatments showed more disperse GFP+ cell accumulation throughout the tumor (Fig 5A) . Accumulation of GFP+ cells was seen at the site of PDGF, SDF1 and VEGF expression in the TME (Fig 5B) . We checked whether the treaments have changed the phenotype of cells with myeloid signatures in the TME. Immunofluorescence study clearly showed increased GFP+ cells alongwith increased CD11b+ and F4/80+ cells in vatalanib, nintedanib and AMD3100 treated groups compared to 9 vehicle (yellow arrows) (Fig 5C) . However, we did not perform immunofluorescence study in NOD-SCID mice.
DISCUSSION
We established a novel chimeric mouse model with more than 70% engraftment efficiency in 2 weeks using 5x10 6 GFP+ bone marrow cells. Our chimera mouse model in nude background is superior to previously published models, which needs 4 weeks to establish with same number of cells engrafted 32, 33 . Chimera in NOD-SCID background showed almost similar engraftment efficiency, implanted with human GBM PDX but could not survive longer for AATs. We noticed increased infiltration of GFP+ BMDCs in TME and increased tumor growth as shown by MRI data following vatalanib, nintedanib and CXCR4 antagonist (AMD 3100). Our observation corroborates with previous report where anti-VEGF recruited increased GFP+ BMDCs in TIB6, B16F1, EL4 and LLC tumor-bearing mice 33 . In our observation, GFP+ BMDCs were invaded throughout tumor but more concentrated at invasive front of tumor and overlapped with expression of VEGF, SDF1 and PDGF.
We used orthotopic mouse model with human glioma cells (U251) that better recapitulate histopathological feature of GBM compared to that of subcutaneous models due to differences in gene expression profile and TME 34, 35 . Previous studies that used U87 cell line, doesn't recapitulate human GBM completely compared to U251 36 . As indicated in human GBMs, orthotopic mice models with U251 revealed similar level of expression of GFAP, S100B, and Together, studies suggest that immune suppressive myeloid cells (especially MDSCs and TAM 60, 61 ) may participate in escape from AATs, may represent a potential biomarker of resistance and a potential therapeutic target in GBM 51 . We also tested combined treatments of vatalanib and AMD3100; however, it did not decrease tumor growth (data not shown). Previously, combined treatment of murine and human VEGF specific antibody and CXCR4 antagonist, POL5551, significantly increased survival of mice bearing GBM 62 . We believe that use of different drugs could be the reason of this differential effect.
Several mechanisms have been known to regulate mobilization and recruitment immature myeloid cells into the TME, e.g. IL17 induced expression of GCSF through NF-κB and ERK signaling helped homing of myeloid cells to the tumor 47 . Bv8 modulated mobilization of
MDSCs from BM to the tumor and promoted angiogenesis 54 . MDSCs can be produced in BM in response to tumor derived factors i.e. GCSF, IL6, GMCSF, IL1β, PGE2 and TNFα, and were recruited to tumor site by CXCL12 and CXCL5 63 . TGFβ signaling in BMDCs is important and recruits MDSCs via CCL2 in TME 64 . CEACAM1 is identified as negative regulator of myeloid cell expansion and recruitment by inhibiting GCSF-Bv8 axis 55 . Similarly, TIMP2 was shown to down regulate expression of immunosuppressive genes controlling MDSC growth such as IL10, IL13, IL11 and chemokine ligand (CCL5/RANTES), and increased IFN-γ and decreased CD40L 65 . Recently, CXCL7 was discovered as an critical chemokine in myeloid cell associated 12 cancer 66 . Our current chimeric mouse model could be used for future molecular mechanism studies of therapeutic resistance in glioma and other solid cancers.
In conclusion, we developed preclinical chimeric mouse models with earlier engraftment efficiency (2 weeks, >70%) compared to available models (4 weeks). We studied the contribution of tumor infiltrated BMDCs in AAT resistance in GBM. Clinical trials involving
AATs have failed so far; therefore, our model may provide a tool to investigate altered myeloid cells and associated molecular networks in GBM. As shown by others before, our study supports that inhibiting key immune suppressive myeloid cells in TME could provide a better therapeutic option in GBM.
MATERIALS AND METHODS
All Animal related experimental procedures were approved by the Institutional Animal Care and
Use Committee and Institutional Review Board of Georgia Regents University (animal protocol #2014-0625). All efforts were made to ameliorate suffering of animals. CO2 with secondary method was used to euthanize animals for tissue collection.
Establishing chimeric mouse model
Chimeric mouse for orthotopic U251 glioma was established with IACUC approved protocol and published method 67 . Transgenic mice with universally expressing GFP under the human ubiquitin C promoter (C57BL/6-tg(UBC-GFP)30Scha) were used as donors (Jackson Laboratory, Main, USA). NCr-nu/nu athymic nude (Charles River, Frederick, MD, USA) and NOD-SCID mice (Harlan laboratory, Indianapolis, USA) were used as recipients, and were whole body irradiated with sub-lethal dose of 6Gy (Cs137). After 24 hours, recipient athymic nude mice were injected intravenous (IV) (n=3) and intraperitoneal (n=3) routes with BM cells 
Animal model of human glioma
Following establishment of chimeric mice, animals were anesthetized with 100 mg/kg ketamine and 15 mg/kg xylazine i.p. The surgical zone was swabbed with betadine solution, the eyes coated with Lacri-lube and the animals were immobilized in a small animal stereotactic device (Kopf, Cayunga, CA). After draping, a 1-cm incision was made 2 mm to the right of the midline 14 to drill a hole 2 mm to the right of the bregma, taking care not to penetrate the dura. A 10µL
Hamilton syringe with a 26G-needle containing U251 tumor cells or GBM PDX (n=2.4x10 5 ) in 3 µl was lowered to a depth of 2.5 mm, and then raised to a depth of 2 mm. During and after the injection, careful note was made of any reflux from the injection site. After completing the injection, we waited 2-3 minutes before withdrawing in a stepwise manner. The surgical hole was sealed with bone wax. Finally, the skull was swabbed with betadine before suturing the skin over the injection site.
In vivo multispectral optical imaging
Multispectral optical images were acquired using excitation profiles of 460-480 nm range and emission of 510 to 570 nm to monitor the GFP color at days 7, 14 and 21 after tumor cell 
Drug treatments
Orthotopically implanted chimeric mice with U251 tumor cells were allowed to grow for 7 days and then started oral treatments of either vehicle or receptor tyrosine kinase inhibitors (vatalanib (50mg/kg/day) 68 and nintadanib (50mg/kg/day) 69 ), daily for two weeks. AMD3100
(10mg/kg/day) 70 treatment was given through ALZET osmotic pumps (DURECT Corporation,
15
CA USA) for two weeks. Seven days waiting period was followed after tumor implantation to mimic clinical scenario, where treatment is being done following detection of tumor.
In vivo magnetic resonance imaging (MRI)
To determine the tumor growth at the end of treatments, all animals underwent MRI on day 22.
All MRI experiments were conducted using a . Two investigators blinded to the animal groups determined tumor volume.
Collection of GFP+ cells and determination of different cell populations
Freshly isolated brain samples were separated into left and right (tumor bearing) hemispheres from each group and were homogenized to pass through 40µ cell strainer to make single cell.
Similarly, cells were collected from spleen and BM. Cells were labeled with antibodies (BioLegend) such as CD45, Gr1, CD11b, F4/80, CD68, CD133, CD31, CD34, CD202b (Tie2), and CD309 (VEGFR2) (other than FITC) to identify BM recruited cell types (GFP+) in the tumor. Flow cytometry data was acquired using Accuri C6 machine (BD Biosciences) and analyzed by BD Accuri C6 software.
Immunofluorescence study
Frozen tissue sections were prepared using standard protocols and later stained for (Santa Cruz Biotechnology) were also determined.
Statistical analysis
Quantitative data was expressed as mean ± SD and analyzed through one way analysis of variance (ANOVA) followed by Fisher's least significant difference (FLSD) post-hoc test.
Group to group analysis was performed using student t-test but analysis between nindtedanib and other groups was performed by non-parametric Mann Wintney test. Differences were considered statistically significant at p value <0.05. Vatalanib treatment significantly increased both myeloid signature (CD68) and endothelial signatures (CD133, CD31, CD202b, CD34) compared to vehicle (A and B) . In addition, significant increase in endothelial cell signatures (CD133 and CD31) was seen in nintedanib group compared to vehicle (A and B). Please note we did not performt CD68, CD202b and View publication stats View publication stats
